Skip to main content
Attorney placeholder

Stefano Quintini

Partner
Technology Transactions
Industry Co-Leader
Life Sciences

Stefano works with innovative technology companies at the forefront of the biotech, digital health, and AI industries, advising them on structuring and negotiating complex, high-value strategic transactions such as collaboration agreements, asset acquisitions, and divestitures.

A strategic partner and trusted advisor to his clients, Stefano takes a holistic, business-first view of each client’s strategy, spending significant time understanding their goals; building deep, long-standing relationships; and using that broader perspective to shape how deals are designed and negotiated. He is deeply involved in the entire lifecycle of strategic partnerships, from early-stage discussions through post-execution alliance management, helping clients navigate ongoing collaborations. He also has extensive experience leading competitive partnering processes, working closely with investment bankers, business development teams, and executive leadership to structure and negotiate strategic collaborations. He plays a key role at the intersection of legal and business strategy, helping clients navigate deal dynamics while ensuring alignment with long-term corporate objectives.

Stefano is very sharp and always has great insights and ideas to solve any issues that arise.”
Life Sciences
Corporate/Commercial Chambers Guide to the USA

Stefano regularly advises on AI-enabled drug discovery collaborations, helping AI-native biotechs and their pharma partners structure first-of-their-kind deals that pair proprietary data, computational platforms, and drug pipelines. His experience spans high-stakes negotiations, bid processes, and deal structuring, both traditional and tech-enabled, allowing clients to maximize value and minimize risk in competitive transactions.

Stefano’s experience also includes structuring a wide range of complex transactions, notably representing Loxo Oncology on all collaboration agreements over several years and on their $8 billion acquisition by Eli Lilly in 2019. His dedication and skills were recognized in 2023 when he was named “Licensing & Collaboration Attorney of the Year” by LMG Life Sciences. This blend of scientific fluency, business acumen, and deal craft means Stefano is equipped to handle a wide variety of matters, from structuring first-of-their-kind AI collaborations to negotiating billion-dollar M&A deals.

Representative Experience

  • Formation Bio in its first-in-class collaboration with Sanofi and OpenAI to build a fine-tuned and custom AI-powered software to accelerate drug development and bring new medicines to patients more efficiently.
  • Chai Discovery, an AI company building a computer-aided design suite for molecules, in its collaboration with Eli Lilly to accelerate biologics discovery using AI.
  • Stoke Therapeutics in its $165M strategic collaboration with Biogen to develop and commercialize zorevunersen for the treatment of Dravet syndrome.
  • Atara Biotherapeutics in its expanded partnership with Pierre Fabre Laboratories for the U.S. and remaining global commercial markets for tab-cel for up to $640M and significant double-digit tiered royalties.
  • Recludix Pharma’s collaboration with Sanofi to develop and commercialize oral small molecule STAT6 inhibitors, valued at over $1.2B.
  • Seagen in multiple transactions, including its strategic collaboration and exclusive license agreement with LAVA Therapeutics, a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma delta T cell engagers.
  • Sutro Biopharma in multiple transactions, including its strategic collaboration and licensing agreement with Astellas Pharma to develop iADCs for three biological targets for $90 million upfront and up to $422.5 million in milestones, and royalties on net sales.
  • Umoja in multiple transactions, including two exclusive option and license agreements with AbbVie to develop multiple CAR-T cell therapy candidates, and a set of multi-target collaborations with IASO Biotherapeutics for the development and commercialization of cell and gene therapies.
  • Scribe Therapeutics in multiple transactions, including its expanded, multi-target collaboration with Sanofi worth more than $1.2B.
  • Sutro Biopharma in its option grant agreement with Vaxcyte, through which Vaxcyte acquired an option to access expanded rights to develop and manufacture cell-free extract, among other rights.
  • Day One Biopharmaceuticals in its $2.5B acquisition by Servier
  • iRhythm Holdings in $287.5M acquisition of VitalConnect
  • Aliada Therapeutics in its $1.4B acquisition by AbbVie
  • Morphic in its $3.2B acquisition by Eli Lilly
  • Shockwave Medical in its $13.1B acquisition by Johnson & Johnson
  • Alpine Immune Sciences in its $4.9B acquisition by Vertex Pharmaceuticals
  • ACELYRIN in its merger with Alumis
  • SomaLogic in its $1B merger with Standard BioTools
  • Chinook Therapeutics in its $3.5B acquisition by Novartis AG

Related to Stefano